Hikal
HIKAL · Pharma > Pharmaceuticals & Drugs · Chairman: Jai Hiremath · MD: Jai Hiremath · Listing date: Feb. 15, 2001 · Employees: 1528 · Navi Mumbai · http://www.hikal.com

Stock Price vs Company Growth
1d
1.2%
1w
3.8%
1m
11.1%
3m
18.7%
6m
29.8%
1y
47.0%
5y
29.9%
10y
15.2%
all
13.3%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 388 1.2%
321
416
Company Overview

Sales
1,821 Cr
Growth: -4.2%
Profit after Tax
73.5 Cr
Growth: 8.4%
Small Cap
4,780 Cr
P/E: 65.0x
Industry P/E: 36.0x
Fundamentals

Sales (Cr) ₹ 1,821
Growth -4.2%
EBITDA 16.0%
P/S 2.6x
Dividend 0.4%
P/E 65.0x
Book Value ₹ 98.2
PEG Ratio -15.5x
ROE 6.2%
P/B 3.9x
Shareholding Pattern

Institutions
Government Pension Fund Global
2.31 %
Promoters
Kalyani Investment Company Limited
31.36 %
Shri Badrinath Investment Pvt Ltd
16.15 %
Shri Rameshwara Investment Pvt Ltd
7.96 %
Sugandha Jai Hiremath
7.84 %
Bf Investment Limited
2.65 %
Others
Si Investments And Broking Private Limited
1.62 %
Llp
0.4 %
Iepf
0.21 %
Increase    Decrease    No change
Company Profile Detailed

Established in 1988 Hikal is a reliable partner to companies in the Pharmaceuticals, Biotech, Agrochemicals and Specialty Chemicals industries. They provide world-class Active Ingredients, Intermediates and R&D services and solutions in a safe, secure and confidential manner. Their advanced infrastructure has been inspected and approved by globally recognized bodies such as the USFDA. Hikal is a company built on enduring relationships.
Investors (60)
Followers (5)